 | Up a level |
Jerusalem, G; Farah, S; Courtois, A; Chirgwin, J; Aebi, S; Karlsson, P; Neven, P; Hitre, E; Graas, M P; Simoncini, E; Abdi, E; Kamby, C; Thompson, A; Loibl, S; Gavilá, J; Kuroi, K; Marth, C; Müller, B; O'Reilly, S; Gombos, A; ... (2021). Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Annals of oncology, 32(10), pp. 1256-1266. Elsevier 10.1016/j.annonc.2021.07.017
Ruggeri, M; Pagan, E; Bagnardi, V; Bianco, N; Gallerani, E; Buser, K; Giordano, M; Gianni, L; Rabaglio, Manuela; Freschi, A; Cretella, E; Clerico, M; Farolfi, A; Simoncini, E; Ciccarese, M; Rauch, D; Ramello, M; Glaus, A; Berardi, R; Pellanda, A Franzetti; ... (2019). Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers. The breast, 47, pp. 85-92. Elsevier 10.1016/j.breast.2019.07.001
Francis, PA; Pagani, O; Fleming, GF; Walley, BA; Colleoni, M; Láng, I; Gómez, HL; Tondini, C; Ciruelos, E; Burstein, HJ; Bonnefoi, HR; Bellet, M; Martino, S; Geyer, Jr. CE; Goetz, MP; Stearns, V; Pinotti, G; Puglisi, F; Spazzapan, S; Climent, MA; ... (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England journal of medicine NEJM, 379(2), pp. 122-137. Massachusetts Medical Society MMS 10.1056/NEJMoa1803164
Pagani, O; Klingbiel, D; Ruhstaller, T; Nolè, F; Eppenberger, S; Oehlschlegel, C; Bernhard, Jürg; Brauchli, P; Hess, D; Mamot, C; Munzone, E; Pestalozzi, B; Rabaglio, Manuela; Aebi, S; Ribi, K; Rochlitz, C; Rothgiesser, K; Thürlimann, B; von Moos, R; Zaman, K; ... (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Annals of oncology, 28(2), pp. 305-312. Oxford University Press 10.1093/annonc/mdw622
Ribi, K; Aldridge, J; Phillips, K-A; Thompson, A; Harvey, V; Thürlimann, B; Cardoso, F; Pagani, O; Coates, A S; Goldhirsch, A; Price, K N; Gelber, R D; Bernhard, J (2012). Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. British journal of cancer, 106(10), pp. 1618-1625. Basingstoke: Nature Publishing Group 10.1038/bjc.2012.156
Karlsson, P; Sun, Z; Braun, D; Price, K N; Castiglione-Gertsch, M; Rabaglio, M; Gelber, R D; Crivellari, D; Collins, J; Murray, E; Zaman, K; Colleoni, M; Gusterson, B A; Viale, G; Regan, M M; Coates, A S; Goldhirsch, A (2011). Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Annals of oncology, 22(10), pp. 2216-26. Oxford: Oxford University Press 10.1093/annonc/mdq735
Aebi, S; Sun, Z; Braun, D; Price, K N; Castiglione-Gertsch, M; Rabaglio, M; Gelber, R D; Crivellari, D; Lindtner, J; Snyder, R; Karlsson, P; Simoncini, E; Gusterson, B A; Viale, G; Regan, M M; Coates, A S; Goldhirsch, A (2011). Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Annals of oncology, 22(9), pp. 1981-7. Oxford: Oxford University Press 10.1093/annonc/mdq754
Colleoni, M; Sun, Z; Martinelli, G; Basser, R L; Coates, A S; Gelber, R D; Green, M D; Peccatori, F; Cinieri, S; Aebi, S; Viale, G; Price, K N; Goldhirsch, A (2009). The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Annals of oncology, 20(8), pp. 1344-51. Oxford: Oxford University Press 10.1093/annonc/mdp024
Rabaglio, M; Sun, Z; Price, K N; Castiglione-Gertsch, M; Hawle, H; Thürlimann, B; Mouridsen, H; Campone, M; Forbes, J F; Paridaens, R J; Colleoni, M; Pienkowski, T; Nogaret, J-M; Láng, I; Smith, I; Gelber, R D; Goldhirsch, A; Coates, A S (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of oncology, 20(9), pp. 1489-98. Oxford: Oxford University Press 10.1093/annonc/mdp033
Bernhard, J; Zahrieh, D; Zhang, J J; Martinelli, G; Basser, R; Hürny, C; Forbes, J F; Aebi, S; Yeo, W; Thürlimann, B; Green, M D; Colleoni, M; Gelber, R D; Castiglione-Gertsch, M; Price, K N; Goldhirsch, A; Coates, A S (2008). Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. British journal of cancer, 98(1), pp. 25-33. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6604092
Gruber, G; Cole, B F; Castiglione-Gertsch, M; Holmberg, S B; Lindtner, J; Golouh, R; Collins, J; Crivellari, D; Thürlimann, B; Simoncini, E; Fey, M F; Gelber, R D; Coates, A S; Price, K N; Goldhirsch, A; Viale, G; Gusterson, B A (2008). Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Annals of oncology, 19(8), pp. 1393-401. Oxford: Oxford University Press 10.1093/annonc/mdn123
Bernhard, J; Zahrieh, D; Castiglione-Gertsch, M; Hürny, C; Gelber, RD; Forbes, JF; Murray, E; Collins, J; Aebi, S; Thürlimann, B; Price, KN; Goldhirsch, A; Coates, AS; International, Breast Cancer Study Group Trial VIII (2007). Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. Journal of clinical oncology, 25(3), pp. 263-70. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2005.04.5393
Keshaviah, A; Dellapasqua, S; Rotmensz, N; Lindtner, J; Crivellari, D; Collins, J; Colleoni, M; Thürlimann, B; Mendiola, C; Aebi, S; Price, K N; Pagani, O; Simoncini, E; Castiglione Gertsch, M; Gelber, R D; Coates, A S; Goldhirsch, A (2007). CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Annals of oncology, 18(4), pp. 701-8. Oxford: Oxford University Press 10.1093/annonc/mdl492
Mauriac, L; Keshaviah, A; Debled, M; Mouridsen, H; Forbes, JF; Thürlimann, B; Paridaens, R; Monnier, A; Láng, I; Wardley, A; Nogaret, JM; Gelber, RD; Castiglione-Gertsch, M; Price, KN; Coates, AS; Smith, I; Viale, G; Rabaglio, M; Zabaznyi, N; Goldhirsch, A; ... (2007). Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Annals of oncology, 18(5), pp. 859-67. Oxford: Oxford University Press 10.1093/annonc/mdm001
Colleoni, M; Gelber, S; Goldhirsch, A; Aebi, S; Castiglione-Gertsch, M; Price, KN; Coates, AS; Gelber, RD; International, Breast Cancer Study Group (2006). Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. Journal of clinical oncology, 24(9), pp. 1332-41. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2005.03.0783
Basser, RL; O'Neill, A; Martinelli, G; Green, MD; Peccatori, F; Cinieri, S; Coates, AS; Gelber, RD; Aebi, S; Castiglione-Gertsch, M; Viale, G; Price, KN; Goldhirsch, A; International, Breast Cancer Study Group (2006). Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. Journal of clinical oncology, 24(3), pp. 370-8. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2005.03.5196
Rudenstam, CM; Zahrieh, D; Forbes, JF; Crivellari, D; Holmberg, SB; Rey, P; Dent, D; Campbell, I; Bernhard, J; Price, KN; Castiglione-Gertsch, M; Goldhirsch, A; Gelber, RD; Coates, AS; International, Breast Cancer Study Group (2006). Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. Journal of clinical oncology, 24(3), pp. 337-44. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2005.01.5784
Regan, MM; Viale, G; Mastropasqua, MG; Maiorano, E; Golouh, R; Carbone, A; Brown, B; Suurküla, M; Langman, G; Mazzucchelli, L; Braye, S; Grigolato, P; Gelber, RD; Castiglione-Gertsch, M; Price, KN; Coates, AS; Goldhirsch, A; Gusterson, B; International, Breast Cancer Study Group (2006). Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. Journal of the National Cancer Institute JNCI, 98(21), pp. 1571-81. Cary, N.C.: Oxford University Press 10.1093/jnci/djj415
Pestalozzi, BC; Zahrieh, D; Price, KN; Holmberg, SB; Lindtner, J; Collins, J; Crivellari, D; Fey, MF; Murray, E; Pagani, O; Simoncini, E; Castiglione-Gertsch, M; Gelber, RD; Coates, AS; Goldhirsch, A; International, Breast Cancer Study Group (IBCSG) (2006). Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Annals of oncology, 17(6), pp. 935-44. Oxford: Oxford University Press 10.1093/annonc/mdl064
Gianni, L; Panzini, I; Li, S; Gelber, RD; Collins, J; Holmberg, SB; Crivellari, D; Castiglione-Gertsch, M; Goldhirsch, A; Coates, AS; Ravaioli, A; International, Breast Cancer Study Group (IBCSG) (2006). Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer, 106(3), pp. 505-13. New York, N.Y.: John Wiley & Sons 10.1002/cncr.21651
